Please login to the form below

Not currently logged in
Email:
Password:

MIT chief financial officer joins Moderna Therapeutics

Israel Ruiz to serve as audit committee chair on its board of directors

US-based biotech Moderna Therapeutics has appointed Israel Ruiz to its board of directors to serve as audit committee chair.

Ruiz is currently executive vice president, treasurer and chief financial officer at Massachusetts Institute of Technology (MIT), where he is responsible for leading all of the institute's administrative and financial operations.

Before taking on his current role in 2011, Ruiz held a number of leadership positions at MIT, including vice president of finance, and lead the institute's digital learning technologies drive.

Ruiz also serves as audit committee chair on Fortive's board of directors, an industrial growth technology specialist.

Dr Noubar Afeyan, co-founder and chairman of Moderna Therapeutics, said: “We are delighted to welcome Israel to Moderna's board of directors.

“His progressive leadership at MIT has helped ensure the continued, unparalleled contributions of the institute on a regional, national and global scale, through education, innovation and entrepreneurship.

“We look forward to leveraging Israel's insights as Moderna evolves into a leading, clinical stage biotechnology company by harnessing the promise of messenger RNA science to improve lives.”

1st March 2017

From: Sales

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Evoke Kyne

Evoke Kyne is an award-winning communications agency that harnesses insight, experience and creativity to advance health and wellbeing around the world. We were founded on the belief that...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...